Terry-Ann Burrell is CFO at Beam Therapeutics Inc. (BEAM). They have made 8 open-market trades across 2 companies since 2021, most recently 2024-07-01.
CIK 0001786484
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BEAM | SELL · 10b5-1 | 2024-04-01 | 2024-04-03 | $32.12 | $350K | -13.6% | -22.3% | -24.1% |
| RXRX | SELL | 2023-07-12 | 2023-07-14 | $12.03 | $2.7M | +16.3% | -20.5% | -46.0% |
| BEAM | SELL · 10b5-1 | 2023-04-03 | 2023-04-05 | $29.74 | $276K | +6.0% | +14.6% | +8.5% |
| BEAM | SELL | 2023-01-26 | 2023-01-30 | $45.08 | $3.3M | +0.8% | -8.7% | -27.2% |
| BEAM | SELL | 2023-01-23 | 2023-01-25 | $45.01 | $1.8M | +5.9% | -14.0% | -32.7% |
| BEAM | SELL | 2023-01-18 | 2023-01-20 | $45.14 | $4.3M | +2.6% | -12.1% | -32.8% |
| BEAM | SELL | 2022-03-31 | 2022-04-04 | $59.11 | $211K | -24.9% | -30.1% | -24.7% |
| BEAM | SELL | 2021-06-30 | 2021-07-02 | $122.00 | $3.7M | -33.9% | -30.0% | -32.7% |
| BEAM | SELL | 2021-06-28 | 2021-06-30 | $107.26 | $7.1M | -29.9% | -28.9% | -29.6% |
| BEAM | SELL | 2021-01-04 | 2021-01-05 | $81.80 | $4.0M | +38.1% | +27.5% | -1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.